Recon: Abbvie cans pacts with Voyager; Bayer sees compounded troubles with COVID-19

• Generic drug approvals still winning the pandemic at US FDA (Pink Sheet)
• BARDA Begins Stockpiling APIs For Critical Drugs (Pink Sheet)
• Report: GoodRx files for IPO (MedCity News)
• CymaBay Reports Positive Results for Seladelpar in Patients with Primary Biliary Cholangitis (Global Genes)
• BARDA drafts Fujifilm Diosynth into its vaccine production effort, offering to also accelerate capacity expansion (BioPharma Reporter)
• AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts (Fierce Biotech)

• MYR Pharmaceuticals gains conditional EC approval for Hepcludex (Pharmaletter)
• Ono reports positive Phase III data for Opdivo combo (Parmaletter)
• Coronavirus compounds trouble for Bayer (Pharmaletter)
• Rerouting Drug Supplies ‘A Priority’ After Brexit Transition Ends (Pink Sheet)
• EU Orphan Law Under Attack Over ‘Flawed Incentives’ (Pink Sheet)
• Indian excipients industry should get govt support to become self-reliant: Experts (Pharmabiz)
• IBM deal to provide the NHS with quicker to access cloud services (Healthcare IT News)
• Sun Pharma latest to sell COVID-19 drug favipiravir in India (Economic Times)

• 4 former FDA commissioners: Blood plasma might be the covid-19 treatment we need (WaPo)
• Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2: Study (Science)
• UK increases COVID-19 vaccine manufacturing capacity (PharmaTimes)
• Gilead faces renewed pressure to pursue remdesivir-like compound to fight Covid-19 (STAT)
• Most Americans support single, national strategy to combat COVID-19 (Ipsos)
• Fauci warns of 'really bad situation' if daily coronavirus cases don't drop to 10K by September (The Hill)
• Fauci: Masking Needs To Be Consistent To Beat Covid-19 (Forbes)
• UK government reserves Wockhardt production line to fill finish COVID-19 vaccines (EPR)
• Covid-19 vaccine trials worry US minority communities (Financial Times)
• Healthcare workers at greater risk of COVID-19 despite 'adequate' PPE, finds research (Pharmaceutical Journal)
• I Was Wrong: We Can’t Skip Phase 3 Vaccine Trials (Forbes)

• Medidata: COVID-19 forcing trials to adapt (Outsourcing-Pharma)
• Oxford Biomedica and Beam Therapeutics sign CAR-T deal (PharmaTimes)
• Immodulon, Champalimaud Foundation team up on ‘difficult to treat’ cancers (PharmaTimes)
• Resistance Is Futile: Is This Herpes Treatment the Future for Antivirals? (Forbes)
• What Ever Happened to NIH’s “Fair Pricing” Clause? (Harvard Law/Petrie Flom)
• Merck bags J&J castoff from Hanmi to expand NASH pipeline (Fierce Biotech)
• Sangamo and Novartis partner on gene therapies for autism (BioPharma-Reporter)
• Novartis’ Ilaris [canakinumab] unexpectedly slashes need for joint replacements from osteoarthritis in key study (Fierce Biotech)

• Device maker Q2 reports show optimism on COVID-19 recovery, but flare-ups keep guidance at bay (MedTechDive)
• Medtronic Ups Its Game in Sacral Neuromodulation for Bowel and Bladder Control (MD+DI) (MedTechDive)
• Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer (360Dx)
• Ancestry relaunches DNA health offerings employing Quest’s next-gen sequencing (Fierce Biotech)

• Bausch Health to pay $45M to settle US charges over Valeant-era accounting (BioPharmaDive)
• No Evidence FDA Sabotaged $375K-A-Year Drug, Judge Says (Law360)
• Judge Recommends Throwing Out Catalyst’s Suit Against FDA (FDA News)
• Sandoz Warns Federal Circuit Enbrel Ruling Invites Patent Abuse (Law360)
• Federal Circuit Trims Bio-Rad IP Win, But $24M Verdict Stays (Law360)
• Full Federal Circuit Won't Revisit Save Of Illumina DNA Patents (Law360)